Oslo / NO. (ok) Orkla Health’s Board of Directors has appointed Isabelle Ducellier (54) as new CEO. She succeeds Hege Holter Brekke, who was appointed EVP + Investment Executive in Orkla ASA on 01 March 2023, in connection with Orkla ASA transforming to an investment company and Orkla Health being established as one of 12 new portfolio companies.
Ducellier comes from the position as CEO for Swedish healthcare company BioGaia group, where she has been since 2018. Prior to that, she has held various managerial positions, such as General Secretary at Swedish Childhood Cancer Fund, Associate Partner at McKinsey, and CEO of Pernod Ricard Sweden. She has a Master’s degree in international marketing from EM Lyon and an Executive MBA from Harvard Business School.
Ducellier has several years of experience of board work in a number of companies, including several of the BioGaia companies, Arcus, Björn Borg, and Jönköping Business School.
Maria Syse-Nybraaten, Chair of the Board of Directors in Orkla Health, commented, «We are very pleased that Isabelle Ducellier has accepted the position as the new CEO of Orkla Health. Her extensive business experience from the consumer health sphere as well as from operating both local and global brands is very relevant for the journey Orkla Health is setting out for. Isabelle’s drive and relevant expertise in the field will make a strong and valuable contribution in the establishment of Orkla Health as a new independent portfolio company».
Ducellier will take up her position in the autumn. She will report to the Board of Directors of Orkla Health.